$42.98

Last traded 2024-06-21 — delisted

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · $1.6B mcap · 8M float · 0.458% daily turnover

Revenue

$629M +9.8% ▲

5Y CAGR: -1.2%

Gross Profit

$305M +13.7% ▲

5Y CAGR: -7.3%

Operating Income

$22M +21.4% ▲

5Y CAGR: -40.8%

Net Income

$54M +111.7% ▲

5Y CAGR: -28.2%

EPS (Diluted)

$1.43 +110.3% ▲

5Y CAGR: -27.7%

EBITDA

$38M -27.1% ▼

5Y CAGR: -36.6%

View Full Income Statement

Line Item	FY2020	FY2021	FY2022	FY2023	FY2024
Revenue	$645M	$549M	$561M	$573M	$629M
YoY Growth	-3.8%	-14.9%	+2.3%	+2.1%	+9.8%
Cost of Revenue	$245M	$252M	$268M	$305M	$324M
Gross Profit	$400M	$297M	$293M	$268M	$305M
Gross Margin	62.0%	54.0%	52.2%	46.8%	48.5%
R&D Expenses	$60M	$60M	$55M	$52M	$65M
SG&A Expenses	$93M	$91M	$114M	$198M	$219M
Operating Expenses	$153M	$152M	$168M	$251M	$283M
Operating Income	$247M	$704M	$184M	$18M	$22M
Operating Margin	38.2%	128.3%	32.8%	3.1%	3.4%
Interest Expense	$725K	$1M	$2M	$1M	$0
Income Before Tax	$298M	-$391M	$78M	$38M	$83M
Tax Expense	$53M	$10M	$20M	$13M	$29M
Net Income	$244M	-$401M	$58M	$25M	$54M
Net Margin	37.9%	-73.0%	10.4%	4.4%	8.6%
EPS (Diluted)	$6.35	$-10.49	$1.55	$0.68	$1.43
EBITDA	$305M	-$414M	$165M	$55M	$38M
Shares Outstanding	38M	38M	38M	38M	38M

Line Item	FY2023 Q1	FY2023 Q2	FY2023 Q3	FY2023 Q4	FY2024 Q1	FY2024 Q2	FY2024 Q3	FY2024 Q4
Revenue	$157M	$130M	$139M	$147M	$159M	$148M	$157M	$165M
Cost of Revenue	$75M	$84M	$75M	$71M	$95M	$75M	$77M	$78M
Gross Profit	$82M	$47M	$64M	$76M	$64M	$74M	$80M	$87M
Gross Margin	52.1%	36.0%	46.0%	51.6%	40.3%	49.7%	50.8%	53.0%
R&D Expenses	$12M	$12M	$13M	$16M	$16M	$14M	$14M	$20M
SG&A Expenses	$56M	$42M	$50M	$50M	$56M	$55M	$50M	$58M
Operating Expenses	$68M	$54M	$63M	$66M	$72M	$69M	$64M	$79M
Operating Income	$14M	-$4M	$1M	$9M	-$8M	$5M	$16M	$9M
Operating Margin	8.9%	-3.1%	0.9%	6.3%	-5.0%	3.2%	10.1%	5.3%
Interest Expense	$2M	$4M	$7M	$0	$0	$0	$0	$0
Income Before Tax	$16M	-$5M	$9M	$18M	$5M	$18M	$33M	$26M
Tax Expense	$2M	-$2M	$2M	$11M	-$5M	$9M	$13M	$11M
Net Income	$14M	-$3M	$7M	$7M	$10M	$9M	$20M	$15M
Net Margin	9.0%	-2.2%	5.2%	4.7%	6.3%	5.8%	12.9%	9.1%
EPS (Diluted)	$0.37	$-0.07	$0.19	$0.18	$0.27	$0.23	$0.54	$0.40
EBITDA	$25M	$3M	$8M	$20M	$6M	$14M	$23M	$18M
Shares Outstanding	38M	38M	38M	38M	38M	38M	38M	38M

TARO NYSE